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Mohamed A. Kharfan-Dabaja,1,2 Ali Bazarbachi3There is growing evidence incriminating B lymphocytes in the pathogenesis of graft-versus-host disease
(GVHD). Better understanding of the role of B lymphocytes has uncovered new therapeutic approaches,
such as CD20 blockade, which appear to be improving outcomes in allogeneic hematopoietic cell transplant
recipients. Administration of the chimeric murine/human anti-CD20 monoclonal antibody, rituximab, prior
to hematopoietic cell allografting or as part of preparative regimens appears to reduce treatment-related
mortality and to improve posttransplant outcomes mainly by decreasing the incidence and severity of acute
GVHD. This beneficial effect of rituximab has not had an impact, to the same extent on the incidence of
chronic GVHD, which remains a significant cause of morbidity and mortality following hematopoietic cell
allografting. Alternatively, rituximab has been shown to be effective for treatment of cGVHD, but data is
limited because of the lack of randomized controlled clinical trials and the small sample size in most of
the published series. Incorporation of rituximab into the therapeutic armamentarium of Epstein-Barr
virus-associated posttransplant lymphoproliferative disorder has clearly improved the overall prognosis of
this dreadful disease. This review highlights the evolving role of CD20 blockade in allogeneic hematopoietic
cell transplantation and the need to continue to refine B cell depletion strategies in this setting.
Biol Blood Marrow Transplant 16: 1347-1354 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Allogeneic hematopoietic cell transplantation, CD20 blockade, RituximabINTRODUCTION
B lymphocytes play a vital role in humoral immu-
nity mainly by producing antibodies (Abs) responsible
for neutralizing antigens such as microbes or toxins
[1]. There is growing data suggesting that B cells also
contribute to immune response by production of
pro-inflammatory cytokines, antigen presentation,
and other immunoregulatory functions [2-7]. Chronic
graft-versus-host disease (cGVHD) shares clinical and
laboratory manifestations analogous to autoimmune
diseases known to produce Abs against host tissues
[8-10]. There is growing evidence incriminating B
lymphocytes in the pathogenesis of GVHD. Miklos
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sponses in vivo. Development of Abs to several mHAs
encoded on the Y chromosome mostly in male recipi-
ents of female hematopoietic cell grafts were strongly
associated with a higher incidence of cGVHD and
maintenance of disease remission [12].
Rituximab, a genetically engineered chimeric mu-
rine/human IgG1 k anti-CD20 monoclonal Ab (mAb),
is currently approved by the United States Food and
Drug Administration for the treatment of various
subtypes of B cell non-Hodgkin lymphomas (NHL).
Clinical studies have demonstrated the efficacy of
rituximab for the treatment of autoimmune diseases
such as rheumatoid arthritis [13,14] and immune
thrombocytopenia purpura (ITP) [15], among others.
Rituximab has been shown to be feasible to combine
with allogeneic hematopoietic cell transplantation (allo-
HCT) preparative regimens, showing an encouraging
lower incidence and severity of acuteGVHD(aGVHD)
[16,17]. Rituximab is also effective for treatment of
corticosteroid-refractory cGVHD [18-26]. We hereby
provide a comprehensive review of the growing role of
CD20 blockade in the setting of allo-HCT.Rituximab as Part of Preparative Regimens for
Hematopoietic Cell Allografting
Developing novel strategies aimed at decreasing
the incidence and severity of GVHD is a definite1347
1348 Biol Blood Marrow Transplant 16:1347-1354, 2010M. A. Kharfan-Dabaja and A. Bazarbachipriority, particularly as the number of allo-HCT using
alternative donors, especially HLA-mismatched, in
recipients of more advanced age continues to grow
worldwide. In 2001, Khouri et al. [16] reported out-
comes using a conditioning regimen of intravenous
fludarabine (Flu) and cyclophosphamide (Cy) in 20
patients, at a median age of 51 years (31-68) years,
with follicular NHL (N 5 18) or small lymphocytic
leukemia (N 5 2) who received granulocyte-colony
stimulating factor (G-CSF) mobilized peripheral
blood stem cells (PBSC) from matched-related donors
(MRD) [16]. Nine (45%) of 20 patients received
rituximab at a dose of 375 mg/m2 on day 26 and
1000 mg/m2 on days 11, 18, and 115 postallograft-
ing. GVHD prophylaxis consisted of tacrolimus plus
methotrexate (5 mg/m2 on days 11, 13, and 16). In
this study, G-CSF 5 mg/kg was administered daily, via
a subcutaneous route, from day 0 until granulocyte
counts reached above 1 103/mL. All patients achieved
hematopoietic recovery with a median time to neutro-
phil engraftment of 11 (10-16) days for the 20 patients
who didn’t receive rituximab and 10 days for the 9 pa-
tients who did receive rituximab. Interestingly, the
cumulative incidence of grade II-IV aGVHD was
only 20% (95% confidence interval [CI]: 8%-45%).
These results are encouraging especially when consid-
ering that rates of aGVHDare generally over 40% [27].
It is unclear whether the beneficial effect of anti-CD20
therapy on aGVHD is the result of B cell depletion per
se or other mechanisms that affect antigen presenta-
tion. However, addition of rituximab did not show
a similar benefit on cGVHD where the cumulative
incidence was reported at 64% (95% CI: 38%-88%).
Recently, a follow-up byKhouri et al. [17] reported
encouraging outcomes in 47 consecutive patients,
at a median age of 53 years (33-68 years), with relapsed
follicular NHL who underwent allo-HCT fromMRD
(N 5 45) or matched-unrelated donors (N 5 2) using
the same regimen of intravenous Flu, Cy, and rituxi-
mab. In this study, rituximab was administered at
a dose of 375 mg/m2 (day 213) and 1000 mg/m2
(days 26, 11, and 18). GVHD prophylaxis consisted
of tacrolimus plus methotrexate (MTX; 5 mg/m2 on
days 11, 13, and 16); an additional MTX dose at
day111, and 3 doses of intravenous equine antithymo-
cyte globulin (ATG; days 25, 24, and 23) were ad-
ministered to allograft recipients of unrelated-donor
grafts. Median donor T cells chimerisms on day 130
and day 190 were 89% and 99%, respectively. Graft
failure was reported in 3 cases (1 primary, 2 secondary).
Estimated progression-free survival (PFS) and overall
survival (OS) at a median of 60 (19-94) months
were 83% (95% CI: 69%-91%) and 85% (95% CI:
85%-95%), respectively. The authors report an
impressive incidence of grade II-IV aGVHD of only
11%.Once again, adding rituximab did not show a sim-
ilar decrease on the overall incidence of cGVHD,which was reported at 60%. However, the incidence
of extensive cGVHD was 36% (95% CI: 25%-53%).
Interestingly, the fact that only 5 patients were still
undergoing immunosuppressive therapy at the last
follow-up would suggest that the addition of rituximab
might have contributed to reducing the overall burden
of cGVHD.
The relative lack of reduction in the overall inci-
dence of cGVHD is particularly puzzling especially
as peripheral blood CD191 cells remained undetect-
able up to 9 months following administration of ritux-
imab [17]. This observation suggests that the role of B
lymphocytes in the pathogenesis of cGVHD is only
a small part of the story. The BMT Clinical Trials
Network (BMT CTN) is currently evaluating a multi-
center phase II clinical trial (BMT CTN protocol
0701) using intravenous Flu, Cy, and rituximab combi-
nation, as previously described [17], in patients with
follicular NHL beyond first complete response to
confirm earlier findings.
Glass et al. [28] reported outcomes of 59 evaluable
(out of 65 enrolled) patients with high-risk aggressive
lymphoma who received a preparative regimen of
Flu, busulfan, and Cy. GVHD prophylaxis consisted
of mycophenolate mofetil plus tacrolimus. Patients
were randomized to receive 4 doses of rituximab start-
ing at days 121 and 1175 postallografting or none.
The 1-year estimated incidence of aGVHD (.grade
I), relapse rate, PFS, and OS in surviving patients
were 73%, 28%, 39%, and 49%, respectively. The
authors report that addition of rituximab did not result
in significant differences in regards to these aforemen-
tioned outcomes.
Furthermore, Kharfan-Dabaja et al. [29] has shown
that adding rituximab, to various Flu-based preparative
regimens, at a dose of 375 mg/m2 on days 11 and 18
postallografting, is feasible and does not affect timely
hematopoietic engraftment in a series of 12 patients
with various CD201 hematologic malignancies [29].
In this series, GVHD prophylaxis consisted of tacroli-
mus plus mycophenolate mofetil (N 5 8) or MTX
(N 5 4). The median donor chimerism at day 190
for unsorted bone marrow (BM), CD3, and CD33 by
polymerase chain reaction/short tandum repeats
(PCR/STR) were 95% (70%-100%), 87.5% (59%-
100%), and 100% (100%), respectively. The incidence
of grade II-IV aGVHD was 74.6%.
The difference in rates of aGVHD among
these studies could be explained by many factors
including the difference in the proportion of patients
receiving alternative donors [28,29] or mismatched
donors [29], the time and dose of rituximab adminis-
tration [16,17,28,29], and the cumulative dose of
rituximab administered to the patient, among others.
Unfortunately, most of the data on the use of
rituximab in preparative regimens is from small data
series. These studies are summarized in Table 1.
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Biol Blood Marrow Transplant 16:1347-1354, 2010 1349Anti-CD20 Therapy in Allogeneic HCTAn ongoing phase II clinical trial, at the Moffitt
Cancer Center, is currently evaluating a novel prepar-
ative regimen for hematopoietic cell allografting
that combines pentostatin, pharmacokinetic-targeted
doses of intravenous busulfan, and rituximab 375
mg/m2 (on days 221, 214, and 27 prior to stem cell
infusion, and on days 11 and 18 postcell infusion).
Of note, in this study rituximab is being administered
only to patients with CD201 expressing malignancies.
Preliminary results of this study will be presented at
the annual meting of the American Society for Blood
and Marrow Transplantation in Orlando, FL in 2010.Prior Administration of Rituximab Results in
Lower Incidence and Severity of aGVHD
The precise mechanisms by which B cell blockade
reduces the incidence and severity of aGVHD remain
in large part is undefined. Ho et al. [30] evaluated an in
vivo purging approach using standard doses of rituxi-
mab administered prior to a conditioning regimen of
BEAM (carmustine, etoposide, cytarabine, and mel-
phalan) plus alemtuzumab. Five patients with follicular
NHL, at a median age of 50.9 years (42.6-55.8 years),
received rituximab 375 mg/m2  4 doses within 12
weeks preceding conditioning therapy. Alemtuzumab
was administered at a dose of 20 mg intravenously on
days25 to21. GVHD prophylaxis consisted of cyclo-
sporine. Patients received G-CSF starting on day 17
posttransplantation until neutrophil engraftment. At
a median of 524 (371-719) days, 4 of the 5 patients
were alive and 3 were in complete remission [30].
The authors report cGVHD in 2 patients (1 limited,
1 extensive). The relative small size of this series and
administration of alemtuzumab during the preparative
phase limit the ability to draw objective conclusions
about the potential benefit of administering rituximab
prior to allograft conditioning.
Ratanatharathorn et al. [31] compared outcomes of
allo-HCT recipients with B cell NHL, registered in
the Center for International Blood and Marrow
Transplant (CIBMTR) database between 1999 and
2004, who received (R[1], N5 179) or did not receive
(R[2], N5 256) prior rituximab. Median age for R(1)
and R(2) groups were similar (P5 .42) at 50 years (22-
67 years) and 50 years (22-70 years), respectively.
Donor recipient sex-matching status was comparable
among the groups (P 5 .76) but the group of patients
who received prior rituximab R(1) had a higher inci-
dence of unrelated donors (32% versus 19%, P 5
.002). Primary endpoint was incidence of grade II-IV
and grade III-IV aGVHD. Prior administration of
rituximab resulted in significant decrease in the cumu-
lative incidence of grade II-IV and grade III-IV
aGVHD (grade II-IV aGVHD in R[1] 5 36% (95%
CI: 29%-43%) and R[2]5 48% (95%CI: 41%-54%),
P 5 0.01; grade III-IV aGVHD in R[1] 5 12%
1350 Biol Blood Marrow Transplant 16:1347-1354, 2010M. A. Kharfan-Dabaja and A. Bazarbachi(95% CI: 8%-18%) and R[2] 5 23% (95% CI: 18%-
29%), P5 .002). Prior rituximab did not influence the
cumulative incidence of cGVHD at 3 years (R[1] 5
56% (95% CI: 48%-64%) versus R[2] 5 53% (95%
CI: 47%-60%), P 5 .58). Interestingly, prior treat-
ment with rituximab was associated with lower
treatment-related mortality in multivariable analysis
(relative risk [RR] 5 0.68, 95% CI: 0.47-1.00, P 5
.05) [31]. These findings suggest a beneficial role of
rituximab, preceding allografting, which results in a
lower incidence and severity of aGVHD and relatively
lower treatment-related mortality. However, this
retrospective analysis is limited by the several short-
comings of large registry studies, particularly a nonho-
mogeneous patient population and donor source,
a variety of conditioning and GVHD prophylaxis
regimens, and observer- and center-dependent differ-
ences in assigning GVHD scores, among others.
Prospective randomized trials are certainly needed to
confirm these findings.Rituximab for Treatment of Corticosteroid-
Refractory cGVHD
cGVHD remains a significant source of morbidity
and impaired quality of life in patients undergoing
allo-HCT. Limited therapies are available to offer pa-
tients with corticosteroid-refractory cGVHD. Addi-
tionally, there is no consensus regarding the best
therapy for patients with cGVHD who fail to respond
or progress on systemic corticosteroids treatment.
Ratanatharathorn et al. [32] described the first case us-
ing rituximab for treatment of cGVHDmanifesting as
refractory ITP, resulting in successful normalization
of platelet counts and remission of cGVHD symp-
toms. Subsequently, Ratanatharathorn et al. [18]
reported an overall response rate (ORR) of 50% in 8
patients treated for refractory cGVHD with rituximab
375 mg/m2 once a week for 4 doses. Other groups
have shown ORR ranging from 43% to 83% using
similar doses and schedule of rituximab [19-23,25].
Interestingly, Von Bonin et al. [24] reported an ORR
of 69% using a lower dose of rituximab at 50 mg/m2
weekly in a series of 13 patients treated for corticoste-
roid-refractory cGVHD.
A systematic review and meta-analysis by Kharfan-
Dabaja et al. [26] reported a pooled proportion ofORR
and mortality of 66% (95% CI: 57%-74%) and 15.8%
(95% CI: 8.3%-25.3%), respectively. The pooled
proportions of ORR according to organ-specific
responses were as follows: skin, 60% (95% CI: 41%-
78%), oralmucosa, 36% (95%CI: 12%-65%), hepatic,
29% (95% CI: 12%-51%), gastrointestinal, 31%
(95% CI: 7%- 62%), and pulmonary, 30% (95% CI:
11%-53%) [26]. Responses to ocular andmusculoskel-
etal cGVHD were also observed, ranging from 13%-
38% and 75%-100%, respectively [18,22,24,26]. Thetotality of evidence demonstrates that the skin is
the most responsive organ, particularly in cases of
lichenoid or sclerodermatous cGVHD [26]. These
results are summarized in Table 2.
Interestingly, administration of rituximab was also
shown to facilitate dose reduction of corticosteroids.
For instance, Mohty et al. [23] reported 86% median
dose reduction of glucocorticoids in 11 (73%) of 15
cases treated with rituximab. Similarly, Cutler et al.
[20] reported a 75%median dose reduction of systemic
corticosteroids more than two-thirds of patients
treated with rituximab. Larger multicenter prospective
trials using a uniform response criterion are needed to
better establish the efficacy of rituximab for the treat-
ment of cGVHD.Rituximab for Treatment of Posttransplant
Lymphoproliferative Disorder (PTLD)
PTLD is a relatively rare but serious complication
of immunosuppression in recipients of solid organ
orHCT [33]. The majority of cases are of B-cell origin
with expression of CD20 [34-36]. PTLD is commonly
associated with active Epstein-Barr virus (EBV)
infection and are invariably found in the setting of
T cell dysfunction [34,37].
The incidence of PTLD in the setting of allo-HCT
has been reported to range between 0.2% to 1.2%, and
themajority of cases occur within the first year of trans-
plantation [38-40]. Patients with acquired aplastic
anemia who received prior ATG were reported to
have an incidence of PTLD as high as 13% [40]. Risk
factors associated with development of PTLD in the
post-allo-HCT setting include T cell depletion, older
age at transplantation, immune deficiency, and ATG
use [38-41]. Use of an anti-CD3 mAb has also been
reported to be associated with PTLD [40].
Early recognition, withdrawal of immunosuppres-
sion, and prompt administration of rituximab have
been shown to improve outcomes in patients with
PTLD in the setting of allogeneicHCT as well as solid
organ transplantation [42-45]. The first successful use
of rituximab for treatment of PTLD in the setting of
allo-HCT was reported by Faye et al. [46] in 1998.
Subsequently, small series have shown that rituximab
administered at a dose of 375 mg/m2 once a week for
4 doses induces ORRs ranging from 66% to 83% in
patients with PTLD [44,47]. Monitoring for EBV
using quantitative PCR and preemptive treatment
with rituximab is a reasonable strategy in recipients
of T cell-depleted allografts or when using ATG
[48,49].
Addition of rituximab to the therapeutic armamen-
tarium for PTLD has clearly improved prognosis of
this previously dreadful disease, which used to be
associated with amortality of over 90% in the preritux-
imab era [39]. Additional strategies involving cellular
Table 2. Studies Evaluating the Efficacy of Rituximab in Patients with Corticosteroid-Refractory cGVHD
Author [Ref], Year Study Design N
Median (Range)
Age
Rituximab Dose 
No. of Doses ORR % Organ-Specific Response
Ratanatharathorn
et al. [18 ], 2003
Retrospective
case series
8 46 (28-58) 375 mg/m2 weekly  4 50% Dermatologic (1/8, 13%)
Ophthalmic (1/8, 13%)
Hepatic (0/8, 0%)
Pulmonary (1/3, 33%)
Canninga-Van Dijk,
et al. [19], 2004
Prospective
(not controlled)
6 37 (17-50) 375 mg/m2 weekly  4 83% Dermatologic (5/6, 83%)
Hepatic (2/5, 40%)
Oral mucosa (5/6, 83%)
Cutler et al. [20], 2006 Prospective
(not controlled)
30* 42 (21-62) 375 mg/m2 weekly  4 68% Dermatologic (52% decrease
in BSA by 1 year)
Okamoto et al. [21], 2006 Prospective
(not controlled)
3 35 (33-42) 375 mg/m2 weekly  4 NE Dermatologic (3/3, 100%)
Ophthalmic (0/3, 0%)
Hepatic (0/2, 0%)
Pulmonary (0/1, 0%)
Zaja et al. [22], 2007 Retrospective 38 48 (22-61) 375 mg/m2 weekly  4 65% Dermatologic (63%)
Ophthalmic (43%)
Hepatic (25%)
Gastrointestinal (75%)
Pulmonary (38%)
Oral mucosa (30%)
Musculoskeletal (80%)
Mohty et al [23], 2008 Retrospective 15 50 (20-67) 375 mg/m2 weekly  4 66% Dermatologic (69%)
Hepatic (66%)
Gastrointestinal (20%)
Pulmonary (0%)
Von Bonin et al. [24], 2008 Retrospective 13 60 (40-67) 50 mg/m2 weekly  3 69% Dermatologic (5/9, 56%)
Ophthalmic (0/4, 0%)
Hepatic (0/3, 0%)
Gastrointestinal (0/2, 0%)
Pulmonary (0/2, 0%)
Oral mucosa (4/8, 50%)
Teshima et al. [25], 2009 Prospective
case series
7 48 (24-55) 375 mg/m2 weekly  4 43%
CR 5 0%
PR 5 43%
SD 5 43%
NE
Kharfan-Dabaja
et al. [26], 2009
Systematic
review/meta-analysis†
111 — 50 mg/m2 and 375 mg/m2 66%‡ Dermatologic (60%)‡
Hepatic (29%)‡
Gastrointestinal (31%)‡
Pulmonary (30%)‡
Oral mucosa (36%)‡
N indicates number of patients evaluated; ORR, overall response rate; CR, complete response; PR, partial response; SD, stable disease; NE, not extract-
able; BSA, body surface area; cGVHD, chronic graft-versus-host disease.
*Only 28 patients were evaluable.
†Did not include Teshima et al. [25], which was not published at time meta-analysis was performed.
‡Represents pooled proportion.
Biol Blood Marrow Transplant 16:1347-1354, 2010 1351Anti-CD20 Therapy in Allogeneic HCTimmunotherapy such as EBV-specific cytotoxic T
lymphocytes have proven to be effective but remain ex-
perimental at this time [50].DISCUSSION
Antigen presentation necessary for optimal T cell
proliferation and response is mediated by a number
of cell types including B lymphocytes [51,52]. B cells
may have both pathogenic and protective roles in
alloreactivity. Crawford et al. [53] has shown that B
cells provide additional and essential antigen presenta-
tion capabilities above that provided by dendritic cells,
promoting expansion and permitting the generation of
memory and effector T cells. Using a B cell-deficient
mouse model where mice received rabbit anti-m IgM
for B cell depletion or rabbit immunoglobulin ascontrol, Schultz et al. [54] demonstrated that B cells
are necessary for T cell priming tominor histocompat-
ibility antigens and development of GVHD. In addi-
tion, clinical studies evaluating adult haploidentical
hematopoietic cell transplantation have shown that
profound T cell and B cell depletion is a promising
strategy that results in fast engraftment kinetics and
relatively reduced rates of GVHD in this setting
[55]. Apart from CD34 cells, CD3/CD19-depleted
allografts also contain CD342 progenitors, graft-
facilitating cells, and natural killer (NK) cells [55].
NK cells have been shown to play a significant role
in modulating and enhancing the ability of B lympho-
cytes to process and present antigens to T cells [56].
Correlative studies have also shown that elevated
levels of B cell activating factor (BAFF), a key regulator
of normal B lymphocyte homeostasis, is associated
with increased disease activity in patients with
1352 Biol Blood Marrow Transplant 16:1347-1354, 2010M. A. Kharfan-Dabaja and A. BazarbachicGVHD [57]. Commercial availability of diagnostic
tests to measure BAFF could provide the basis for
preemptive strategies that may allow for earlier
therapeutic intervention in patients with cGVHD
[57]. This could potentially reduce morbidity from
cGVHD, especially if treatment is initiated before
severe clinical symptomatology and irreversible organ
damage ensues. Moreover, direct inhibition of BAFF
represents an attractive B cell depleting strategy for
treatment of GVHD. A recombinant fully humanized
IgG1 l mAb, namely belimumab, capable of binding
BAFF/BlyS with high affinity and preventing its bind-
ing to BAFF receptors, was found to be well tolerated
and to reduce peripheral B cell levels in patients with
systemic lupus erythematosus [58].
Better understanding of the role of B lymphocytes
in the pathogenesis of GVHD has uncovered new
therapeutic approaches, such as CD20 blockade, that
are improving outcomes in allogeneicHCT recipients.
As detailed above, administration of rituximab prior to
allogeneic HCT or as part of preparative regimens
appears to improve clinical outcomes, mostly by
decreasing the incidence and severity of aGVHD
[16,17,31]. This beneficial effect of rituximab has not
had an impact on the incidence of cGVHD to the
same extent. Interestingly, cGVHD occurs despite
undetectable levels of B lymphocytes, for up to
9 months, following administration of rituximab [17].
This clearly highlights our limited understanding of
the role(s), direct or indirect, of B lymphocytes in the
pathogenesis of cGVHD. The heterogeneity of ritux-
imab dosing regimens used in clinical studies (or small
series) reported herein in regard to dose administered,
frequency of administration, and cumulative rituximab
exposure is noteworthy. Studies reported by Khouri
et al. [16,17] suggest that using higher doses of
rituximab (1000 mg/m2) results in lower incidence of
aGVHD [16,17]. However, prospective randomized
studies comparing high-dose (1000 mg/m2) versus
standard dose (375 mg/m2) rituximab using similar
schedule of administration are necessary to address
this issue.
Rituximab has also been shown to be effective for
treatment of cGVHD involving various organs [18-
26]. Responses to rituximab were observed even at
a weekly low dose of 50 mg/m2 [24]. The ability of
rituximab to facilitate tapering down the dose of
corticosteroids is particularly remarkable because
chronic exposure to increased cumulative doses of
corticosteroids results in detrimental outcomes in
patients with corticosteroid-refractory cGVHD. Con-
ceptually, earlier intervention with CD20 blockade in
combination with corticosteroids, represents a logical
approach that could potentially facilitate a faster
taper of corticosteroids. An ongoing phase II clinical
trial led by Stanford University (ClinicalTrials.gov
Identifier: NCT00350545) is evaluating whetheradministration of 4 weekly doses of rituximab as
first-line treatment for cGVHD will allow tapering
prednisone to a dose of 0.25 mg/kg/day by 6 months
without clinical flare-up.
As the use of rituximab continues to expand, it is
important to balance the benefits of rituximab therapy
against the potential risks of developing serious infec-
tions [59]. A theoretical concern with CD20 blockade
in the setting of hematopoietic cell allografting is the
potential to blunt the adoptive graft-versus-tumor re-
sponse by interfering with B cell antigen presentation
and consequently tumor-directed alloreactivity.
Finally, incorporation of rituximab into the thera-
peutic armamentarium of PTLD has clearly improved
the overall prognosis of patients who develop PTLD
following allo-HCT or solid organ transplantation.
Early recognition of PTLD, especially in high-risk
cases, discontinuation of immune suppression when-
ever possible, and prompt initiation of rituximab,
before rapid progression, are strategies that result in
improved responses when treating PTLD.ACKNOWLEDGMENTS
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